Tuesday, September 15, 2026

#Bundibugyo Virus Disease #Outbreak, #DRC, #Uganda - Weekly #Report 18, Data as of 13 Sept. '26 (WHO, summary): 7,258 cases and 3,510 deaths in DRC



{Excerpts}


{Click on Image to Enlarge}

___

Event description

Democratic Republic of the Congo

    The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic  of the Congo has expanded to a seventh province, with the first confirmed  case reported in Bulu Health Zone, Sud-Ubangi, a province bordering the  Central African Republic and the Republic of the Congo. 

    This latest geographic expansion heightens concern about further spread  towards international borders, while transmission within the country remains  increasingly heterogeneous across affected provinces and health zones. 

    Since External Situation Report #17, a further 572 confirmed cases and 284 confirmed deaths have been reported, bringing the cumulative total to  7258 confirmed cases, including 3510 deaths [case fatality ratio (CFR) 48.4%], as of 13 September 2026. 

    Ituri remains the principal focus but its relative contribution continues to  decline, accounting for 78.0% of cumulative confirmed cases, while transmission  continues to increase in Nord-Kivu and persists in Haut-Uélé

    The outbreak now affects 62 health zones across seven provinces, with  Bulu Health Zone in Sud-Ubangi being the latest affected.

    At the national level, daily incidence remains high and fluctuating, with  the seven-day moving average declining from its mid-August peak, followed by a modest rebound in early September. This national pattern masks increasingly divergent provincial trajectories. 

    Ituri continues to decline from its mid-August peak but remains at a high  level, while Nord-Kivu is experiencing a sharp and sustained increase, reaching its  highest incidence since the start of the outbreak and increasingly driving the  national trajectory. 

    Transmission in Haut-Uélé remains sustained but has declined from its  August peak. 

    Tshopo shows a recent increase from a low baseline, while Bas-Uélé  continues to report sporadic transmission, and no recent transmission is evident in  Sud-Kivu. 

    Overall, the epidemic is becoming more geographically heterogeneous,  with declining transmission in Ituri and Haut-Uélé occurring alongside rapid  intensification in Nord-Kivu, renewed activity in Tshopo and continued geographic  expansion to new areas.


Figure 1. Daily national trend in confirmed Bundibugyo virus disease cases, with  seven-day moving average, by date of report, Democratic Republic of the Congo, as of 13 September 2026


{Click on Image to Enlarge}

___

    During the most recent 21 days (24 August – 13 September 2026), 1674  confirmed cases were reported nationally. 

    Compared with 1782 cases during the preceding 21-day period (3 – 23 August 2026), this represents a decrease of 108 cases (−6.1%). Reported  cases declined by 25.0% in Ituri, from 1338 to 1004, and by 16.7% in Haut-Uélé,  from 120 to 100. 

    In contrast, cases increased sharply by 76.1% in Nord-Kivu, from 314 to  553, while Tshopo increased from 8 to 13 cases and Bas-Uélé from 2 to 3  cases. One case was also reported in the newly affected province of Sud-Ubangi  during the latest period. Consequently, Ituri’s contribution to newly reported cases  fell markedly from 75.1% to 60.0%, while Nord-Kivu’s contribution nearly  doubled from 17.6% to 33.0%; Haut-Uélé’s contribution declined slightly from  6.7% to 6.0%. 

    Overall, the modest 6.1% national decline masks a pronounced geographic redistribution of transmission, with the substantial decline in Ituri  increasingly offset by rapidly intensifying transmission in Nord-Kivu and continued geographic expansion.

    During the same period, 830 confirmed deaths were reported nationally,  compared with 973 deaths during the preceding 21 days, representing a decrease of 143 deaths (−14.7%). The national decline was driven largely by  Ituri, where reported deaths decreased from 706 to 495 (−29.9%), while deaths  also declined in Haut-Uélé, from 50 to 31 (−38.0%). 

    In contrast, deaths increased substantially in Nord-Kivu, from 213 to 299  (+40.4%). Consequently, Ituri’s contribution to newly reported deaths fell  markedly from 72.6% to 59.6%, while Nord-Kivu’s contribution increased from  21.9% to 36.0%; Haut-Uélé’s contribution declined from 5.1% to 3.7%. Tshopo  and Bas-Uélé each reported two deaths during the latest period, while one death  was reported in Sud-Ubangi. 

    Overall, the national reductions in both cases (−6.1%) and deaths (−14.7%) were driven predominantly by declining transmission and mortality in  Ituri and mask sharply divergent provincial trajectories. In particular, the  simultaneous increases in cases (+76.1%) and deaths (+40.4%) in Nord-Kivu  indicate substantial intensification of the outbreak there, with the province now  accounting for one-third of newly reported cases and more than one-third of  newly reported deaths nationally.

(...)

    Additionally, during the most recent 21 days (24 August – 13 September  2026), 49 of the 62 affected health zones (79.0%) reported at least one new  confirmed case, while 13 (21.0%) reported no new cases. Health zones reporting  no cases were Adja, Ariwara, Aungba, Kambala and Mahagi in Ituri; Goma in  Nord-Kivu; Gombari in Haut-Uélé; Lubunga, Tshopo and Wanie-Rukula in Tshopo;  Miti-Murhesa in Sud-Kivu; and Buta and Viadana in Bas-Uélé.

    Provincial trends also mask important differences between health zones.  In Ituri, where cases declined by 25.0% overall, several health zones continued to  increase, notably Komanda (22 to 76; +245.5%), Mangala (92 to 116;  +26.1%), Lita (56 to 65; +16.1%) and Mongbwalu (50 to 61; +22.0%). 

    In  contrast, major transmission areas declined substantially, including Bunia (384 to 285; −25.8%), Nizi (210 to 120; −42.9%), Rwampara  (258 to 106; −58.9%) and Nia-Nia (89 to 46; −48.3%). 

    Nord-Kivu shows the opposite pattern, with broad-based intensification  rather than an increase confined to a few hotspots. Cases increased in Katwa (162  to 175; +8.0%), Beni (53 to 111; +109.4%), Butembo (51 to 101;  +98.0%) and Musienene (27 to 46; +70.4%), alongside transmission in newly or  recently affected health zones. Haut-Uélé declined overall, but this also concealed  a marked increase in Pawa, from eight to 38 cases (+375%), while Isiro and  Wamba declined.

(...)

    Weekly confirmed deaths peaked at 364 during 10 – 16 August, before  declining to 302 and 270 over the following two weeks. Deaths subsequently  increased to 276 during 31 August – 6 September and further to 284 during 7 –  13 September. 
    
    The composition of mortality, however, shifted in the latest week.  Community deaths decreased from 207 to 193 (−6.8%), while deaths in  treatment facilities increased from 69 to 91 (+31.9%). Consequently, the  proportion of deaths occurring in the community declined from its peak of 75.0%  to 68.0%, although it remains substantially higher than in most earlier weeks.

    The persistence of high community mortality may reflect multiple barriers  along the pathway to care, including delayed detection and notification, delayed  referral or transfer to treatment facilities, limited recognition of illness or  perceived severity, geographic and transport barriers, care-seeking outside formal  health facilities, and community acceptance or trust. These factors may result in  patients reaching treatment facilities late or dying before referral can be  completed.

    The continued predominance of community deaths, despite expanding  treatment capacity, therefore suggests that increasing bed capacity alone may be  insufficient and reinforces the need to strengthen early case detection, rapid 
referral and community-level pathways to timely care.

(...)

Risk Assessment

    The risk of further spread remains very high within the Democratic Republic of the Congo. This assessment reflects sustained transmission,  continued geographic expansion, high mortality, population mobility, insecurity  and persistent response challenges. 
    
    A two-week invasion-risk forecast has identified 20 currently unaffected  health zones at elevated risk of transmission. 
    
    In descending order of predicted risk, these are Rethy, Watsa, Nyarambé,  Biringi, Dungu, Makoro, Karisimbi, Angumu, Rutshuru, Nyiragongo, Niangara,  Linga, Kirotshe, Bafwagbogbo, Alimbongo, Jiba, Poko, Rwanguba, Kamango and  Kibirizi. 
    
    The highest predicted risks are concentrated in Ituri and Haut-Uélé,  reinforcing the need for riskbased preparedness and readiness measures. 

    The risk is considered high for neighbouring countries sharing land  borders with the Democratic Republic of the Congo and low elsewhere in Africa  and globally. 

    The second IHR Emergency Committee, convened on 18 August 2026, also  reviewed the evolving situation and emphasized that the outbreak remains  far from controlled, and continues to constitute a Public Health Emergency of International Concern.

(...)


Situation interpretation

    The outbreak remains uncontrolled and increasingly heterogeneous,  with declining transmission in Ituri masking rapid intensification in Nord-Kivu, and  continued geographic expansion, including to Sud-Ubangi. Response efforts should prioritize targeted interventions in emerging and persistent hotspots,  particularly strengthening early detection, contact tracing, rapid isolation and  referral, IPC and community engagement. Approaches contributing to declining  transmission in areas of Ituri should be identified, consolidated and rapidly  adapted and scaled up in areas where transmission is increasing. Preparedness  should also be reinforced in high-risk health zones and along domestic and cross- border corridors to limit further geographic spread.

Source: 

Link: https://www.afro.who.int/countries/democratic-republic-of-congo/publication/ebola-bundibugyo-virus-disease-outbreak-3

_____

The First 100 Days of Five #Ebola #Outbreaks — #DRC, #Uganda, and West #Africa, 2007–2026 (MMWR, Sept. 15 '26)

 


Summary

    ° What is already known about this topic?

        § The Democratic Republic of the Congo (DRC) is experiencing its largest and deadliest Ebola disease outbreak, which is also the largest Ebola outbreak caused by Bundibugyo virus and the second largest Ebola outbreak worldwide.

    ° What is added by this report?

        § The 2026 Ebola outbreak resulted in 5,458 confirmed cases and 2,606 deaths in DRC in the first 100 days after initial detection, indicating rapid growth. No previous Ebola outbreak caused >800 cases during the first 100 days.

    ° What are the implications for public health practice?

        § This Ebola outbreak appears to be expanding faster than any previously documented Ebola outbreak, with seven times as many cases 100 days after initial detection than the 2014 Ebola outbreak in West Africa, the largest outbreak worldwide. Urgent implementation of public health interventions to identify cases, trace contacts, and limit transmission are needed to bring the outbreak under control.


Abstract

The first 100 days after identification of an outbreak are important to understanding transmission dynamics, impact of early public health interventions, and trajectory of potential future cases and deaths. A large Ebola disease outbreak in the Democratic Republic of the Congo (DRC), which has become the country’s largest and deadliest, is ongoing. To better understand the current outbreak, this report compared metrics from the first 100 days of this outbreak with those of four past Ebola outbreaks. The historic outbreaks of Ebola disease selected for this comparison include the two largest (the 2014 outbreak in West Africa and a 2018 outbreak in DRC), and the only two previous outbreaks caused by Bundibugyo virus (the 2007 outbreak in Uganda and the 2012 outbreak in DRC). This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.*

Source: 


Link: http://dx.doi.org/10.15585/mmwr.mm7537e1

____

#Nuclear #Conflict in Eastern #Europe: #Climate #disruption and #Radiological fallout

 


Abstract

Geopolitical tensions in Eastern Europe underscore the urgency of addressing the climatic and radiological consequences of a regional nuclear conflict. Using an Earth System Model, we simulate a hypothetical nuclear conflict at the Ukraine-Russia border that releases 5 Teragram (Tg; 5 million tons) of black carbon (BC), the dominant driver of the post-detonation climate response, into the stratosphere. We adopt the 5 Tg BC post-detonation emission scenario because it is a widely modelled scenario for a “limited” regional nuclear conflict (typically India–Pakistan), enabling a direct comparison with prior studies. The extended stratospheric lifetime of BC induces hemispheric climate disruption: the Northern Hemisphere cools by ~1 °C in year-1, with anomalies of −5 °C in Russia and −4 °C in the United States; surface solar radiation declines by ~30 W m−2 over the US; and precipitation decreases by ~40% across mid-latitude croplands. Stratospheric warming alters subtropical and polar jets, displacing the Intertropical Convergence Zone ~2–6° southward, delaying climate recovery by ~6 years. Long-lived radionuclides transported with BC disperse globally, with ~40% depositing in the Southern Hemisphere. These findings underscore the importance of nuclear-risk reduction and provide a robust benchmark for food-security and humanitarian-impact assessments.

Source: 


Link: https://www.nature.com/articles/s44407-026-00064-7

____

#Habitat-Mediated #Spillover #Risk of #Andes #Hantavirus in Oligoryzomys longicaudatus: A Mechanistic Eco-Epidemiological Model

 


Abstract

Andes hantavirus (ANDV) is a rodent-borne orthohantavirus associated with hantavirus cardiopulmonary syndrome in southern South America. Its maintenance and spillover risk depend on the ecology of its principal reservoir, Oligoryzomys longicaudatus, and on environmental changes that alter habitat availability, host abundance, and human–rodent interfaces. We developed a mechanistic eco-epidemiological model that couples effective habitat cover to an SIR framework for ANDV transmission in O. longicaudatus. Habitat degradation and compensatory restoration modify rodent carrying capacity, natality, and the force of infection, which depends on infected host load relative to instantaneous ecological capacity. We derived the habitat equilibrium, the basic reproduction number ℛ0, and the time-dependent effective reproduction number ℛ𝑒(𝑡) and evaluated infection-burden and threshold indicators across degradation-restoration scenarios. The  analysis shows that ℛ0 is independent of equilibrium habitat cover because susceptible abundance scales with carrying capacity at the disease-free  equilibrium. In contrast, ℛ𝑒(𝑡), cumulative incidence, and infected load depend on transient habitat-mediated crowding. Restoration increases reservoir abundance and absolute infection burden, whereas degradation can reduce abundance while increasing crowding-driven transmission pressure and prolonging supercritical windows. These results identify ecological conditions under which habitat change may intensify reservoir infection pressure and guide One Health surveillance at human–rodent interfaces.

Source: 


Link: https://www.mdpi.com/1999-4915/18/9/1024

____

Avian #Influenza #Report: September 6 - 12 '26 (Wk 37) (HK CHP, Sept. 15 '26): 1 new confirmed #human case of #infection with #H9N2 virus in #China

 


{Excerpt}

(...)

Avian influenza A(H9N2):

    ° Guangxi Zhuang Autonomous Region:

        § A two-year-old boy with onset on August 23, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk37.pdf

____

#Philippines - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification [FINAL]

 


___


{Yellow-vented Bulbul. By DexDroid29 - Nikon P500Previously published: First publicated in wikipedia, CC0, https://commons.wikimedia.org/w/index.php?curid=112929120}

___



{Lowland white-eye. By Gideon Ferrer - Facebook and donated by Owners, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=152574672}

___

A wild Yellow-vented bulbul and a wild Lowland white-eye birds in the Pangasinan Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7837

_____

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics Weekly #Update (CDC, September 15 '26): #H1N1pdm09 flu virus & #SARS-CoV-2 PQ.16.1.1 predominated

 


{Excerpts}

(...)

    The CDC pointed out that the domestic influenza epidemic is rising and in its epidemic season. 

    In the 36th week (September 6th-12th), there were 136,796 outpatient and emergency room visits for influenza-like illnesses, an increase of 16.5% compared to the previous week. 

    Additionally, last week (September 8th-14th), there were 92 new cases of severe influenza complications (79 H1N1, 5 H3N2, and 8 untyped A cases) and 21 deaths (18 H1N1, 2 H3N2, and 1 untyped A case). 

    Laboratory monitoring data shows that the influenza virus currently circulating in the community is mainly type A, with type A H1N1 accounting for 82.2%. 

    This flu season has seen a cumulative total of 1,421 severe cases (800 H1N1, 503 H3N2, 28 untyped type A, and 90 type B) and 274 deaths (149 H1N1, 104 H3N2, 9 untyped type A, and 12 type B). 

    The majority of severe cases are among those aged 65 and above (65.0%) and those with a history of chronic diseases (82.7%). 68.3% of those affected have not received the flu vaccine this season.


    According to data from the Taiwan Centers for Disease Control (CDC), the COVID-19 epidemic in Taiwan is declining, but it is still in its epidemic period. 

    In week 36 (September 6-12), there were 17,847 outpatient and emergency room visits related to COVID-19, a 13.3% decrease compared to the previous week (August 30-September 5). 

    Last week (September 8-14), there were 53 new severe cases and 18 local deaths

    Since October 2025, there have been a cumulative total of 675 locally transmitted cases of COVID-19 complicated by severe illness, of which 124 have died. 

    Severe cases are predominantly among those aged 65 and above (73.3%) and those with a history of chronic diseases (82.8%). 83.6% of these cases have not received the COVID-19 vaccine this season. 

    In the past four weeks, the most prevalent local variants have been NB.1.8.1 and PQ.16.1.1.

(...)

Source: 


____

#Australia, #H5 avian #influenza events in #wildlife (DAFF, as of September 14 '26)

 


{Excerpt, Summary}

(...)

Event data

    ° 542 *Positive events

    ° 44,354 Hotline reports


    As of 4pm AEST, 14 September 2026, Australia has 542 confirmed events of H5 bird flu in wildlife.

    ° 10 in Western Australia (WA)

    ° 295 in South Australia (SA)

    ° 32 in New South Wales (NSW)

    ° 2 in Queensland (QLD)

    ° 165 in Victoria (VIC)

    ° 37 in Tasmania (TAS)

    ° 1 in Other Territories*

    ° * Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.

___


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Monday, September 14, 2026

Co-occurrence #networks from #wetland #bird #surveys predict #H5N1 genetic similarity between wild birds with strong effects of time, space and viral clustering

 


Abstract

The emergence of zoonotic and epizootic diseases has had devastating consequences for human and animal health, including wildlife conservation. Yet, surveillance of multi-host disease systems is particularly challenging due to complex transmission pathways across many species. Social network analysis has been applied to simple transmission systems, but empirical applications to wild, multi-species systems are scarce. Here, we combined high pathogenicity avian influenza (HPAI) viral genomes, a zoonotic virus of pandemic potential, with a large citizen-science database of wild bird co-occurrence to test how multi-species social network structure predicts transmission dynamics. We linked viral genetic distance, 20,103 pairwise comparisons between 214 unique genomes from 172 dyads of 20 host species, to co-occurrence network metrics for those species. Both relative species association and raw co-occurrence frequency predicted lower maximum viral genetic divergence, more similar viruses between more associated species, beyond what would be expected through random mixing and independently of sequencing effort. Time and space between samples were also strong predictors of genetic similarity. Our results suggest that network models can be used to detect pathogen transmission through communities of wild birds, offering real prospects for wildlife disease surveillance and prediction.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.1101/2025.06.17.659947v5

____

Sunday, September 13, 2026

#Pathogenesis and natural history of the #Bundibugyo species of #Orthoebolavirus in nonhuman #primates

 


Abstract

The current outbreak of Bundibugyo virus (BDBV) in Africa is a global public health concern particularly as there are no licensed medical countermeasures (MCM). Well characterized animal models that accurately replicate human BDBV infection are needed to develop effective MCM. We exposed 21 cynomolgus monkeys (CM) to BDBV to examine the progression and natural history of BDBV disease (BVD). BVD was more protracted than reported for Ebola and Sudan infection in CM with a lower lethality rate of 67% consistent with lower human BVD mortality rates. IHC and spatial proteomics identified CD209+, CD68+, and/or HLA-DR+ macrophages and dendritic cells as early targets of BDBV. These infected cells frequently colocalized with fibrin and infiltrating MPO+ neutrophils and S100A9+ myeloid-derived suppressor cells, consistent with the development of an active inflammatory response and early coagulopathy. Transcriptomic and proteomic analyses of the circulating immune response correspondingly reflected a cytokine-driven hyperinflammatory state in CM that succumbed to disease. Surviving animals resolved systemic inflammation by the study endpoint; however, BDBV antigen was identified in immune privileged tissues with lesion-associated inflammation aligning with known post-Ebola sequela in humans. This data should assist in identifying weaknesses in the disease course that can be exploited to develop new MCM.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69, U19AI109945

The University of Texas Medical Branch at Galveston, https://ror.org/016tfm930, N/A

Source: 


Link: https://doi.org/10.64898/2026.08.10.743937

____

Staircase in Capri, John Singer Sargent (1878)

 


{Click on Image to Enlarge}

___

Public Domain.

Source: 


Link: https://www.wikiart.org/en/john-singer-sargent/staircase-in-capri-1878

____

Assessment of immune #response induced by ChAdOx1 nCoV-19, Sputnik V, and BNT162b2 #vaccines during #COVID19 #outbreak in #Mexican population: Gene expression of the #cytokine storm

 


Highlights

    • The molecular immune response triggered by vaccines against COVID-19 was analyzed.

    • The evaluated genes were ACE2, CD79B, TMPRSS2, CTSB, FCGR3A and MB-1.

    • These vaccines induce a protective immune response through various mechanisms.

    • Vaccines regulate the immune response through pro- and anti-inflammatory cytokines.


Abstract

Introduction

COVID-19 vaccines using different technological platforms may induce distinct molecular responses. Characterizing gene-expression patterns after vaccination and in fatal COVID-19 may identify pathways associated with vaccination and severe disease.

Objective

To compare immune-, inflammatory-, and SARS-CoV-2-entry-related gene expression after AstraZeneca, Pfizer, or Sputnik V vaccination and with unvaccinated fatal COVID-19.

Materials and methods

Eighty Mexican adults were included: AstraZeneca (n = 19), Pfizer (n = 20), Sputnik (n = 21), and unvaccinated fatal COVID-19 (n = 20). Expression of 11 genes was measured by qPCR at days 30 (D30) and 60 (D60) after vaccination.

Statistical analysis

Longitudinal differences were analyzed by two-way repeated-measures ANOVA. Comparisons with fatal COVID-19 were exploratory. Benjamini–Hochberg correction controlled false discovery rate at 5%.

Results

No differences among vaccines were detected at D30. At D60, IL-10, IL-2, and CD79A differed among selected vaccine groups. Longitudinally, FCGR3A decreased in AstraZeneca and Sputnik, ACE2 decreased in Pfizer and Sputnik, and TMPRSS2 increased in Sputnik. Fatal COVID-19 showed predominantly higher expression of several genes than vaccinated groups. Notably, IL-2 and ACE2 were consistently higher in fatal COVID-19 than in all vaccinated groups at both time points.

Discussion and conclusions

Post-vaccination transcriptional profiles were dynamic, with selected differences emerging at D60, whereas fatal COVID-19 exhibited a distinct profile characterized predominantly by higher expression of immune-, inflammatory-, and viral-entry-related genes. Consistent IL-2 and ACE2 differences highlight molecular pathways potentially associated with severe disease. The observational design, however, precludes causal attribution to vaccination.

Perspectives

Longitudinal studies with appropriate controls are needed to establish the biological significance of these transcriptional patterns.

Source: 


Link: https://doi.org/10.1016/j.meegid.2026.106025

____

#Australia, #H5 avian #influenza events in #wildlife (DAFF, as of September 13 '26)

 


{Excerpt, Summary}

(...)

    As of 4pm AEST, 11 September 2026, Australia has 521 confirmed events of H5 bird flu in wildlife.

    ° 10 in Western Australia (WA)

    ° 286 in South Australia (SA)

    ° 25 in New South Wales (NSW)

    ° 2 in Queensland (QLD)

    ° 162 in Victoria (VIC)

    ° 36 in Tasmania (TAS)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.

(...)


Positive events by species

{As of September 13 2026}


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

#Coronavirus Disease Research #References (AMEDEO, September 13 '26)

 


    Eur J Radiol

  1. GARCIA-HIDALGO C, Naval-Baudin P, Garcia-Garcia JI, Viveros-Castano M, et al
    Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters.
    Eur J Radiol. 2026;205:113218.
    PubMed         Abstract available


    J Infect

  2. QIAN J, Zhang Z, Zhang L
    SARS?CoV?2 spike CTD suppresses host metabolism but restricts viral entry through a PDZ?dependent trade?off.
    J Infect. 2026 Sep 11:106857. doi: 10.1016/j.jinf.2026.106857.
    PubMed        

  3. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
    Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
    J Infect. 2026;93:106851.
    PubMed        

  4. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
    J Infect. 2026;93:106850.
    PubMed        


    J Med Virol

  5. TIKHONOVA IV, Dyukina AR, Grinevich AA, Tutukina MN, et al
    Immunological Properties of SARS-CoV-2 S and M Protein Fragments and Their Effects on Respiratory Burst in Human Neutrophils.
    J Med Virol. 2026;98:e71151.
    PubMed         Abstract available

  6. SREELAKSHMI PR, Wagh P, Sarje P, Shinde T, et al
    Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.
    J Med Virol. 2026;98:e71145.
    PubMed         Abstract available


    J Travel Med

  7. VAN GENDEREN PJJ, van Sprang ENM
    Artificial Intelligence and Complementary Digital Health Technologies Across the Travel Medicine Continuum: A Narrative Review.
    J Travel Med. 2026 Sep 9:taag082. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  8. KIRK J, Sives S, Rayment A, Tappin A, et al
    Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
    J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
    PubMed         Abstract available

  9. LIU M, Duong MTH, Laocharoensuk T, Aryal B, et al
    Mutations in the macrodomain 1 of nsp3 attenuate PEDV virulence in vivo without impairing in vitro replication.
    J Virol. 2026 Sep 9:e0125126. doi: 10.1128/jvi.01251.
    PubMed         Abstract available

  10. YU R, Zhang L, Zhou P, Zhang Z, et al
    Low-pH-induced conformational changes in the spike protein promote porcine deltacoronavirus infection by enhancing viral binding efficiency to the porcine aminopeptidase receptor.
    J Virol. 2026 Sep 9:e0116826. doi: 10.1128/jvi.01168.
    PubMed         Abstract available

  11. ALVARADO RE, Chen J, Lokugamage KG, Zhou Y, et al
    Antagonism of stress granules is key to SARS-CoV-2 infection and pathogenesis.
    J Virol. 2026 Sep 8:e0099226. doi: 10.1128/jvi.00992.
    PubMed         Abstract available

  12. YAO Z, Zhu Y, Liu N, Hu Y, et al
    The alpha-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.
    J Virol. 2026 Sep 8:e0106726. doi: 10.1128/jvi.01067.
    PubMed         Abstract available


    Life Sci

  13. HAN D, Beurel E
    The spike protein S1 of SARS-CoV-2 promotes Th17 cell-dependent stress-induced depressive-like behaviors in mice.
    Life Sci. 2026 Sep 8:124672. doi: 10.1016/j.lfs.2026.124672.
    PubMed         Abstract available


    N Engl J Med

  14. HAYDEN FG, Sax PE
    Ensitrelvir for Covid-19 Postexposure Prophylaxis. Reply.
    N Engl J Med. 2026;395:1039.
    PubMed        

  15. SUZUKI J, Imai H, Endo S
    Ensitrelvir for Covid-19 Postexposure Prophylaxis.
    N Engl J Med. 2026;395:1039.
    PubMed        


    Travel Med Infect Dis

  16. TIMPERLEY EK, Swithenbank L, Beeching NJ, Tang E, et al
    General physicians still fail to take travel histories.
    Travel Med Infect Dis. 2026 Sep 9:103021. doi: 10.1016/j.tmaid.2026.103021.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, September 13 '26)

 


    Antimicrob Agents Chemother

  1. PENG Z, Yuan H, Huang J, Lin X, et al
    A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle.
    Antimicrob Agents Chemother. 2026 Sep 9:e0028426. doi: 10.1128/aac.00284.
    PubMed         Abstract available


    BMC Pediatr

  2. BOZZOLA E, Piccotti E, D'Auria E, Trapani S, et al
    RESPIRIAMO - Italian hospital surveillance for lower respiratory tract infections: a multicenter retrospective cohort study of respiratory syncytial virus-associated hospitalizations in children under 2 years of age.
    BMC Pediatr. 2026;26:853.
    PubMed         Abstract available


    J Infect

  3. ZHU X, Deng Y, Xiao G, Zhang J, et al
    Re-emergence of H10N3 Avian Influenza Viruses in China: Evolutionary Dynamics and Emerging Zoonotic Risk.
    J Infect. 2026 Sep 7:106848. doi: 10.1016/j.jinf.2026.106848.
    PubMed        


    J Virol Methods

  4. EZEANYAEGBU CN, Toledo NP, Corkum CP, Nelder M, et al
    Evaluation of one-step amplicon-based targeted enrichment for SARS-CoV-2 whole-genome sequencing using the Midnight amplicon scheme.
    J Virol Methods. 2026;346:115448.
    PubMed         Abstract available

  5. KAZEMIAN S, Pedroza S, Santana-Pereira ALR, Neasham PJ, et al
    An enhanced multisegment RT-PCR method for influenza A virus sequencing: Improved performance and reduced preparation time over traditional methods.
    J Virol Methods. 2026;347:115453.
    PubMed         Abstract available


    PLoS Comput Biol

  6. QUILTY BJ, Chapman LAC, Munday JD, Wong KLM, et al
    Disentangling the drivers of heterogeneity in SARS-CoV-2 transmission from data on viral load and daily contact rates.
    PLoS Comput Biol. 2026;22:e1014715.
    PubMed         Abstract available

  7. SONG P, de Vlas SJ, Emery T, Coffeng LE, et al
    Mapping spatial colleague connectivity patterns from individual-level registry data to inform regional pandemic interventions.
    PLoS Comput Biol. 2026;22:e1014721.
    PubMed         Abstract available

  8. PANT B, Lalovic M, Kiss IZ, Santillana M, et al
    The paradox of neglecting changes in behavior: How standard epidemic models misestimate both transmissibility and final epidemic size.
    PLoS Comput Biol. 2026;22:e1014746.
    PubMed         Abstract available

  9. YUAN Z, Zhang X, Lin G, Zou Q, et al
    AET5: A transcriptome-guided molecular generation framework with contrastive self-supervised learning.
    PLoS Comput Biol. 2026;22:e1014703.
    PubMed         Abstract available

  10. BENHAMOU W, Howerton E, Park SW, Viboud C, et al
    Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.
    PLoS Comput Biol. 2026;22:e1014784.
    PubMed         Abstract available


    PLoS Med

  11. LENGLART L, Titomanlio L, Alberti I, Almeida L, et al
    Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis.
    PLoS Med. 2026;23:e1005223.
    PubMed         Abstract available


    PLoS One

  12. KWON K, Jang CY, Kim W, Son J, et al
    Kinetics of the PASC Index in Long COVID.
    PLoS One. 2026;21:e0357670.
    PubMed         Abstract available

  13. BATTU S, Moore AR, Lebold K, Pacheco-Navarro A, et al
    Outcomes of immunocompromised and non-immunocompromised patients in the ICU diverge late in the pandemic.
    PLoS One. 2026;21:e0357181.
    PubMed         Abstract available

  14. JI M, Dong H, Xu Y, Wang Y, et al
    Development of a multiplex real-time PCR assay with fluorescence probe-melting-curve analysis for one-tube detection of respiratory pathogens.
    PLoS One. 2026;21:e0357377.
    PubMed         Abstract available

  15. GONG X, Liu L, Lu Y, Zhang G, et al
    Sleepless in America: A social sensing study of pandemic-era sleeplessness using nighttime social media data.
    PLoS One. 2026;21:e0356547.
    PubMed         Abstract available

  16. BHATIA A, Elser J, Carrell SJ, Kronmiller B, et al
    Correlation assessment of SARS-CoV-2 variants and their subvariants present in clinical and wastewater samples in Oregon, USA (February 7, 2021 - February 26, 2022) using the Freyja bioinformatics approach.
    PLoS One. 2026;21:e0357591.
    PubMed         Abstract available

  17. MOHD YUSOFF H, Yew SQ, Mohd Nawi A, Mohd Tohit N, et al
    Prevalence and risk factors of adverse work outcomes among manufacturing workers with Long COVID in Malaysia - A nationwide study.
    PLoS One. 2026;21:e0357125.
    PubMed         Abstract available

  18. VALDES-LOPEZ JF, di Filippo D, Penagos S, Hernandez-Sarmiento LJ, et al
    SARS-CoV-2 infection induces functional impairment of vitamin D receptor signaling to drive interleukin 6-dependent hyperinflammation in mononuclear phagocytes.
    PLoS One. 2026;21:e0357030.
    PubMed         Abstract available

  19. AMARSANAA J, Nguyen TXT, Khan MSR, Kadoya Y, et al
    The dynamics of loneliness: A longitudinal exploration of transitions in Japan across the COVID-19 period, 2020-2024.
    PLoS One. 2026;21:e0358269.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. LI L, Nguyen L, Qu H, Wu Q, et al
    Increased receptor binding and spike glycosylation, remodeled immune escape of surging SARS-CoV-2 subvariant BA.3.2.2/RE.2.2/Cicada.
    Proc Natl Acad Sci U S A. 2026;123:e2614163123.
    PubMed         Abstract available


    Vaccine

  21. BUCKLIN R, Gauthreaux N, Faber E, Askelson N, et al
    Listening to micropolitan community leaders to support pandemic response efforts.
    Vaccine. 2025;60 Suppl 1:127255.
    PubMed         Abstract available

  22. HOLLIDAY RC, Darkwa A, Brooks GA, Akintobi TH, et al
    Developing counter-narratives to address COVID-19 misinformation among 18-24 year olds in community and campus settings.
    Vaccine. 2025;60 Suppl 1:127135.
    PubMed         Abstract available

  23. HEIMAN SL, Geiger N
    Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.
    Vaccine. 2026;91:129046.
    PubMed         Abstract available

  24. DUTTA S, Ngemera D, Jaillard P, Juneja S, et al
    Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa.
    Vaccine. 2026;91:128994.
    PubMed         Abstract available

  25. CAMPBELL STATLER M, Bishop-Royse J, Sampson AT, Martin M, et al
    Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.
    Vaccine. 2026;91:129024.
    PubMed         Abstract available

  26. KIM SJ, Kim HW, Son SE, Song JH, et al
    Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.
    Vaccine. 2026;91:129059.
    PubMed         Abstract available

  27. FAHFOUHI Y, Fievez S, Cohen R, Levy C, et al
    A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.
    Vaccine. 2026;91:129036.
    PubMed         Abstract available

  28. BERIKOPOULOU MM, Tatsi EB, Siahanidou T, Michos A, et al
    Systematic review of the mutations in the active antigenic site O of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis.
    Vaccine. 2026;91:129069.
    PubMed         Abstract available

  29. NUNES JPDS, Daher IP, Pires ADS, Yamamoto MM, et al
    Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.
    Vaccine. 2026;91:129073.
    PubMed         Abstract available

  30. MONOI A, Endo A, Kriznar M, Suzuki M, et al
    Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.
    Vaccine. 2026;91:129079.
    PubMed         Abstract available

  31. SCHRARSTZHAUPT IN, Diaz-Quijano FA
    Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024).
    Vaccine. 2026;91:129096.
    PubMed         Abstract available

  32. ALAMI A, Lewis M, El-Chaar D, Walker M, et al
    Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.
    Vaccine. 2026;91:129070.
    PubMed         Abstract available

  33. DENG L, Ye X, Chen X, Hu X, et al
    Secretory expression of tetrameric neuraminidase enhanced by signal peptide optimization elicits robust immunity against influenza infection in mice.
    Vaccine. 2026;92:129118.
    PubMed         Abstract available

  34. SANBORN J, Robertson MM, Penrose K, Rane M, et al
    Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort.
    Vaccine. 2026;92:129126.
    PubMed         Abstract available

  35. LU J, Ouyang Z, Huang F, Xie X, et al
    Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study.
    Vaccine. 2026;92:129100.
    PubMed         Abstract available

  36. THAKKAR V, Aryan Y, Gautam S, Joshi R, et al
    Influence of vaccine delivery route on immune imprinting in influenza vaccination.
    Vaccine. 2026;92:129109.
    PubMed         Abstract available

  37. TORAIH EA, Hussein MH, Thomas SJ, Aiash H, et al
    Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals.
    Vaccine. 2026;91:129001.
    PubMed         Abstract available

  38. CABURNAY CA, Fu QJ, Carter T, Butler T, et al
    Identification of best outreach strategies and delivery modalities for population subgroups for COVID-19 vaccination.
    Vaccine. 2026;60 Suppl 1:128721.
    PubMed         Abstract available

  39. CANACA G, Vicuna B, Hess JM, Cruz TH, et al
    From engagement to ownership: a qualitative study of a community-academic partnership to promote COVID-19 vaccine confidence among Latino/Hispanic communities in New Mexico.
    Vaccine. 2026;60 Suppl 1:128583.
    PubMed         Abstract available

  40. STIEHL E, Negrete M, Flores G, Federmeyer L, et al
    Empowering communities during the COVID-19 pandemic: insights from trusted messengers about their work addressing COVID-19 vaccine hesitancy.
    Vaccine. 2026;60 Suppl 1:128559.
    PubMed         Abstract available

  41. NUNO T, Soto S, Sepulveda R, Sierra LA, et al
    The Arizona prevention research center vaccine confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.
    Vaccine. 2025;60 Suppl 1:127970.
    PubMed         Abstract available

  42. HARA-HUBBARD KK, Beaulieu A, Mendiola A, Gandhi P, et al
    Strategies for addressing COVID-19 vaccine equity with intermediaries, prevention research centers, and the vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127847.
    PubMed         Abstract available

  43. CHUVILEVA YE, Kuiper NM, Ramakrishnan A, Goodman K, et al
    Weaving a public health network: Process and results from an evaluation of CDC's Prevention Research Centers Vaccine Confidence Network.
    Vaccine. 2025;60 Suppl 1:127636.
    PubMed         Abstract available

  44. ALMUKHTAR S, McWhirter N, Mendiola A, Samuel S, et al
    Exploring lingering COVID-19 vaccine hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
    Vaccine. 2025;60 Suppl 1:127664.
    PubMed         Abstract available

  45. BEAULIEU A, LaMonaca K, Higginbottom J, Foster J, et al
    Utilizing the Program Impact Pathways framework for improving COVID-19 vaccine confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
    Vaccine. 2025;60 Suppl 1:127623.
    PubMed         Abstract available

  46. JEFFERS A, Kuiper NM, Ramakrishnan A, Swarna H, et al
    Building trust in community-academic partnerships: Strategies for enhancing vaccine confidence and demand - Lessons from Prevention Research Centers.
    Vaccine. 2025;60 Suppl 1:127624.
    PubMed         Abstract available

  47. MCGEE RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, et al
    Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.
    Vaccine. 2025;60 Suppl 1:127587.
    PubMed         Abstract available

  48. BORG A, Goulding M, Minkah P, Perrone D, et al
    Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.
    Vaccine. 2025;60 Suppl 1:127586.
    PubMed         Abstract available

  49. SAVAS LS, Cuccaro P, Zhang K, Hernandez R, et al
    Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.
    Vaccine. 2025;60 Suppl 1:127554.
    PubMed         Abstract available

  50. TOTZKAY D, Fraustino JD, Costello LM, Jarrett T, et al
    Building on West Virginia's innovative COVID-19 public health communication: associations between vaccination beliefs and vaccination messaging, partisanship, and social vulnerability.
    Vaccine. 2025;60 Suppl 1:127555.
    PubMed         Abstract available

  51. O'CONNOR MH, Nyman AL, Ali S, Rothenberg R, et al
    Increasing vaccine uptake in a refugee resettlement community with high social vulnerability.
    Vaccine. 2025;60 Suppl 1:127552.
    PubMed         Abstract available

  52. STIEHL E, Borg A, Cullen JP, Mendiola A, et al
    Engaging trusted messengers in public health response: Key strategies to building community trust among CDC'S prevention research center's vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127474.
    PubMed         Abstract available

  53. HARA-HUBBARD KK, Flores Moreno MG, Sanchez M, Abdi N, et al
    The partnership for vaccine confidence: community-academic partnerships to promote COVID-19 vaccines to underserved urban and rural communities using the listen, plan, act, evaluate process.
    Vaccine. 2025;60 Suppl 1:127487.
    PubMed         Abstract available

  54. MALLICK K, Handunge VL, Emmons KM, Blondet L, et al
    Engaging a community health ambassador model to promote COVID-19 vaccine in three Massachusetts communities.
    Vaccine. 2025;60 Suppl 1:127464.
    PubMed         Abstract available


    Virology

  55. ISHIGAKI H, Otaki K, Kitagawa N, Ishida H, et al
    Pathogenicity of SARS-CoV-2 Omicron subvariants JN.1, EG.5.1, and BA.2.86.1 in immunologically naive cynomolgus macaques.
    Virology. 2026;624:111036.
    PubMed         Abstract available

  56. LIU Z, Fan M, Zheng Y, Zeng Y, et al
    Transcriptome screening identifies circRNA-INSR as a novel host factor associated with avian influenza virus replication.
    Virology. 2026;625:111072.
    PubMed         Abstract available

  57. MILLER AK, Heremia L, Waller SJ, Blanchard SL, et al
    Evaluating sampling strategies for the detection of avian influenza viruses in the environment.
    Virology. 2026;625:111069.
    PubMed         Abstract available


    Virus Res

  58. ZHAO Y, Fan H
    Clinical impact of baloxavir-induced PA I38T/M substitutions in diverse influenza populations: a systematic review and meta-analysis.
    Virus Res. 2026;373:199797.
    PubMed         Abstract available

My New Space

Most Popular Posts